A pharmaceutical manufacturer typically needs a company or other entity, investment registration where foreign investors are involved, a factory site with the necessary environmental and fire approvals, a drug manufacturing licence from the DGDA, and registration of each product before it is sold. Plans and layouts are usually reviewed before the licence is granted, and good manufacturing practice inspections follow. Import of raw materials and machinery requires its own approvals. The sequence matters, because some approvals depend on others. We prepare a licensing roadmap that matches the construction and commissioning plan, and keep it updated as approvals arrive.

A foreign company can sell through a local importer and distributor, appoint a local agent, license its products to a Bangladeshi manufacturer, or establish its own presence. Imported products must be registered with the DGDA, usually through a local importer, and import policy may restrict products that are already manufactured locally in sufficient quantity. Licensing to a local manufacturer is often the fastest route to market. We compare these options, draft the distribution, licensing or supply agreements, and advise on product registration ownership, so that the foreign company keeps control of its pharmaceutical registrations and brands.

Foreign investment is generally permitted in pharmaceutical manufacturing and in healthcare services, subject to the sector rules, licensing requirements and the investment registration process now run through Invest Bangladesh. Foreign investors often enter by acquiring or partnering with an existing licensed operator, because licences and product registrations take time to build. Foreign exchange rules apply to capital inflows, dividends and repatriation. We advise on structure, approvals and the regulatory diligence needed to understand what licences, registrations and liabilities come with a target, and on protecting the investor's position in a joint venture.

Bangladesh regulates the prices of a list of essential medicines, and the DGDA also oversees the pricing of other products through approval or indicative price processes. Price changes generally need regulatory engagement, and labels must show approved prices. Pricing affects manufacturers, importers and distributors, and pricing clauses in supply and licensing agreements should anticipate regulatory decisions rather than assume free pricing. Policy can change, especially as costs and exchange rates move. We help pharmaceutical clients understand the current approach for their products and build commercial terms that remain workable if prices are capped or revised.

Telemedicine sits at the meeting point of medical practice rules, drug sale rules, consumer protection, digital commerce and data protection law. Key questions include whether doctors on the platform are registered with the BMDC, how prescriptions are issued, whether medicines can be sold or delivered online, how patient identity and consent are handled, and where data is stored. The Personal Data Protection Act 2026 adds clear duties around health data. We review the service model, draft platform terms and doctor agreements, and set up data protection controls before launch, so that growth does not outpace compliance.

Clinical trials and bioequivalence studies generally need ethics approval through the national research ethics process, associated with the Bangladesh Medical Research Council, as well as approval from the DGDA where investigational products are involved. Sponsors and contract research organisations also need clinical trial agreements with sites and investigators, insurance and indemnity arrangements, informed consent documents and data protection terms. Import of investigational products requires its own permissions. We help sponsors and research organisations plan approvals, draft agreements and align local requirements with international standards used by global sponsors. Local sites need clear guidance.

As a least developed country, Bangladesh has benefited from flexibility under the WTO TRIPS rules on pharmaceutical patents, which has supported local production of medicines still patented elsewhere. Graduation from LDC status will reduce that flexibility after any applicable transition, and Bangladesh's patent law and export market access will matter more. Companies need to review their product portfolios, licensing strategies, patent landscape and export plans. The timing and transition arrangements depend on government and international decisions. We help pharmaceutical clients assess exposure and plan licensing, partnership and portfolio changes in good time. Pharmaceutical exporters should review their markets now.

Beyond the usual corporate and financial checks, a buyer should verify every manufacturing and trading licence, the registration status of each product, pending variations and renewals, inspection reports, quality and recall history, pricing approvals, environmental clearances, import permits, key supply and licensing agreements, and any regulatory or product liability disputes. Ownership of product registrations and brands can be a particular issue in family-owned groups. We run regulatory diligence alongside commercial and financial work and translate the findings into price adjustments, warranties, indemnities and conditions in the acquisition documents.